臨床検査54巻11号

2010年10月発行

特集 新時代のワクチン戦略について考える 各論 2. 任意接種のワクチン

6) HPV

著者： 吉川裕之¹

所属機関： ¹筑波大学大学院人間総合科学研究科婦人周産期医学

ページ範囲：P.1371 - P.1375

HPV16とHPV18のウイルス様粒子(VLP)をワクチンとして用いた子宮頸癌の予防が本邦でも始まった．中和抗体でHPVが細胞に感染する前にブロックする．臨床試験でCIN2/3発生予防効果がほぼ100％であり，重篤な有害事象はない．10～26歳程度までの女性への接種が特に推奨される．このワクチンはHPV16/18型特異的で，近い将来において，約70％の子宮頸癌の予防が可能になる．

参考文献

1) Munoz N, Bosch FX, de Sanjose S, et al:Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med　348：518-527，2003

2) Harper DM, Franco EL, Wheeler CM, et al:Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18:follow-up from a randomised control trial. Lancet　367：1247-1255，2006

3) Konno R, Dobbelaere KO, Godeaux OO, et al:Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women:interim analysis of a phase II, double-blind, randomized controlled trial at month 7. Int J Gynecol Cancer　19：905-911，2009

4) 神谷斎，奥谷まり絵：10～15歳の日本人健康女性を対象とした子宮頸癌予防ワクチンCervarix (HPV-16/18AS04アジュバントワクチン)の免疫原性と安全性の評価．小児臨　62：2451-2460，2009

5) Garland SM, Hernandez-Avila M, Wheeler CM, et al:Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med　356：1928-1943，2007

6) Paavonen J, Jenkins D, Bosch FX, et al:Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:an interim analysis of a phase III double-blind, randomised controlled trial. Lancet　369：2161-2170，2007

7) FUTURE II Study Group:Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med　356：1915-1927，2007

8) Joura EA, Leodolter S, Hernandez-Avila M, et al:Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions:a combined analysis of three randomised clinical trials. Lancet　369：1693-1702，2007

9) Ault KA;Future II Study Group:Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ:a combined analysis of four randomised clinical trials. Lancet　369：1861-1868，2007

10) Paavonen J, Naud P, Salmeron J, et al:Efficacy of human papillomavirus(HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA):final analysis of a double-blind, randomised study in young women. Lancet　374：301-314，2009

11) GlaxoSmithKline Vaccine HPV-007 Study Group:Sustained efficacy and immunogenicity of the human papillomavirus(HPV)-16/18 AS04-adjuvanted vaccine:analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet　374：1975-1985，2009

12) David MP, Van Herck K, Hardt K, et al:Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine:modeling of sustained antibody responses. Gynecol Oncol　115：S1-S6，2009

13) Descamps D, Hardt K, Spiessens B, et al:Safety of human papillomavirus(HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention:a pooled analysis of 11 clinical trials. Hum Vaccin　5：332-340，2009

14) Miura S, Matsumoto K, Oki A, et al:Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer　119：2713-2715，2006

15) Onuki M, Matsumoto K, Satoh T, et al:Human papillomavirus infections among Japanese women:age-related prevalence and type-specific risk for cervical cancer. Cancer Sci　100：1312-1316，2009

16) Nakagawa S, Yoshikawa H, Onda T, et al:Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer　78：1935-1941，1996

17) Schiffman M, Castle PE:The promise of global cervical-cancer prevention. N Engl J Med　353：2101-2104，2005

18) Markowitz LE, Dunne EF, Saraiya M, et al:Quadrivalent Human Papillomavirus Vaccine:Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm　Rep 56：1-24，2007